Treatment of the bone marrow failure in Fanconi anemia patients with danazol
article
OA: closed
CC0
⤵ 5 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (42)
- Androgens and liver tumors: Fanconi's anemia and non‐Fanconi's conditions via openalex
- A review of 76 patients with myelodysplastic syndromes treated with danazol via openalex
- Danazol as first-line therapy for aplastic anemia via openalex
- Danazol therapy for aplastic anemia refractory to immunosuppressive therapy via openalex
- Endometriosis via openalex
- Epithelial ovarian cancer: testing the 'androgens hypothesis' via openalex
- doi:10.1182/blood-2006-07-036657 via openalex
- doi:10.1016/j.mrfmmm.2009.05.006 via openalex
- doi:10.4161/cc.10.11.15818 via openalex
- doi:10.1016/j.ymthe.2005.04.021 via openalex
- doi:10.1182/blood-2002-07-2170 via openalex
- doi:10.1016/s1081-1206(10)60424-3 via openalex
- doi:10.1016/s0301-472x(02)00782-8 via openalex
- doi:10.1016/j.bbmt.2011.01.001 via openalex
- doi:10.1016/j.bbmt.2010.11.027 via openalex
- doi:10.1007/s00228-009-0771-z via openalex
- doi:10.1002/humu.10266 via openalex
- doi:10.1002/humu.20125 via openalex
- doi:10.1038/sj.ejhg.5200248 via openalex
- W4240884067 via openalex
- W6638166880 via openalex
- W6650854197 via openalex
- doi:10.1542/peds.2006-3303 via openalex
- doi:10.1111/j.1365-2141.2005.05721.x via openalex
- doi:10.1038/356763a0 via openalex
- doi:10.1001/archpedi.1959.02070020295002 via openalex
- doi:10.1056/nejmcp0803977 via openalex
- doi:10.1056/nejmra0809889 via openalex
- doi:10.1002/(sici)1098-1004(1996)8:2<140::aid-humu6>3.0.co;2-f via openalex
- doi:10.1111/j.1651-2227.2010.02116.x via openalex
- doi:10.1038/nsmb1252 via openalex
- doi:10.1002/humu.10166 via openalex
- doi:10.1182/blood-2004-05-1852 via openalex
- doi:10.1016/j.semarthrit.2010.03.005 via openalex
- doi:10.1182/blood.v95.2.422 via openalex
- doi:10.1056/nejm196105112641901 via openalex
- doi:10.1182/blood.v95.4.1493.004k35_1493_1498 via openalex
- doi:10.1055/s-2008-1065326 via openalex
- doi:10.1097/00043426-200401000-00006 via openalex
- doi:10.1007/bf01955250 via openalex
- doi:10.1016/j.drudis.2007.01.003 via openalex
- doi:10.1182/blood-2008-09-178871 via openalex
Cited by (5)
- Danazol treatment for poor graft function after hematopoietic stem cell transplantation: a single centre experience 2025
- Androgen therapy in inherited bone marrow failure syndromes: analysis from the Canadian Inherited Marrow Failure Registry 2020
- Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita 2020
- Danazol: An Effective and Underutilised Treatment Option in Diamond-Blackfan Anaemia 2019
- Nontransplant therapy for bone marrow failure 2016
Source provenance
- openalex
- last seen: 2026-05-14T06:08:44.784461+00:00
License: CC0
· commercial use OK